Zura(US:ZURA)2025-08-14 12:20Financial Position - Zura Bio reported cash and cash equivalents of $154.5 million as of June 30, 2025, expected to fund operations through 2027[8]. - The total assets as of June 30, 2025, were $157.8 million, down from $179.5 million as of December 31, 2024[20]. - The accumulated deficit increased to $189.3 million as of June 30, 2025, compared to $155.9 million at the end of 2024[20]. Operating Expenses - Research and Development (R&D) expenses increased to $8.7 million in Q2 2025, up from $5.5 million in Q2 2024, primarily due to advancements in clinical studies[10]. - General and Administrative (G&A) expenses rose to $9.4 million in Q2 2025, compared to $6.2 million in Q2 2024, driven by increased compensation and external spending[11]. - For the three months ended June 30, 2025, total operating expenses were $18,062 million, an increase from $11,759 million in the same period of 2024, representing a 53.5% increase[22]. - Research and development expenses for the three months ended June 30, 2025, were $8,704 million, up from $5,539 million in 2024, reflecting a 56.5% increase[22]. - General and administrative expenses increased to $9,358 million for the three months ended June 30, 2025, compared to $6,220 million in 2024, marking a 50.5% increase[22]. Net Loss - The net loss for Q2 2025 was $16.0 million, or $0.17 per share, compared to a net loss of $10.3 million, or $0.17 per share, in Q2 2024[12]. - The net loss for the three months ended June 30, 2025, was $15,993 million, compared to a net loss of $10,329 million in the same period of 2024, indicating a 55.0% increase in losses[22]. - The net loss attributable to Class A Ordinary Shareholders of Zura for the three months ended June 30, 2025, was $15,993 million, compared to $12,666 million in 2024, a 26.0% increase[22]. - The net loss per share attributable to Class A Ordinary Shareholders of Zura for the three months ended June 30, 2025, was $0.17, unchanged from the same period in 2024[22]. Clinical Studies - Zura Bio initiated the TibuSHIELD Phase 2 clinical study for tibulizumab in moderate to severe hidradenitis suppurativa in Q2 2025, with topline data expected in Q3 2026[4]. - The company continued its Phase 2 TibuSURE clinical study for systemic sclerosis, with topline data anticipated in Q4 2026[5]. - The company is conducting preclinical research on crebankitug and evaluating torudokimab for potential therapeutic benefits in immune-mediated diseases[6][7]. Other Financial Metrics - Total other income, net for the three months ended June 30, 2025, was $(2,069) million, compared to $(1,430) million in 2024, reflecting a 45.0% increase in other losses[22]. - Loss from operations for the three months ended June 30, 2025, was $(18,062) million, compared to $(11,759) million in 2024, a 53.5% increase in operational losses[22]. - The company reported an interest income of $(1,717) million for the three months ended June 30, 2025, down from $(2,196) million in 2024, a decrease of 21.8%[22]. Shareholder Information - Weighted-average Class A Ordinary Shares used in computing net loss per share for the three months ended June 30, 2025, were 94,289,954, compared to 74,947,369 in 2024, an increase of 25.8%[22]. - Zura Bio appointed a new Chief Financial Officer and a new board member to support ongoing growth and development[8].